Whistle-blower: Walgreen saw "unique opportunity" to substitute more expensive meds

09/13/2011 | BNET

A whistle-blower lawsuit accuses Walgreen executives of encouraging pharmacists to switch patients' Zantac tablet prescriptions to a Par Pharmaceuticals capsule version that cost up to three times as much. Par representatives alerted Walgreen managers that Medicaid limited reimbursement for the tablet version but not for the capsule version. Walgreen's director of pharmacy marketing allegedly told pharmacists that substituting the easier-to-swallow capsules for the tablets was "a unique opportunity" to interact with patients.

View Full Article in:

BNET

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC